Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MPT0B640 in Advanced Solid Malignancies
NCT04294875Phase 1Withdrawn
- Sponsor
- J INTS BIO
- Start
- Dec 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of MPT0B640 in solid tumor (advanced stage) and metastatic solid tumors, sponsored by J INTS BIO. Primary endpoint: Maximum Tolerated Dose at 28 days. Planned start Dec 2025; status: withdrawn.
02
Drugs
MPT0B640
03
Conditions
solid tumor (advanced stage)metastatic solid tumors
Beyond the preview
Go deeper on NCT04294875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04294875.